FDA, COVID-19 and vaccine
Digest more
Top News
Overview
Impacts
FDA announces cucumber recall
Digest more
Top News
Impacts
For context
The US Food and Drug Administration will now require Covid-19 vaccines from Pfizer/BioNTech and Moderna to use expanded warning labels with more information about the risk of a rare heart condition after vaccination.
The FDA warns that longtime users of popular allergy medications may experience "severe itching" after stopping use.
Federal health officials will no longer routinely approve annual COVID-19 shots for younger adults and children who are healthy
Explore more
The programmed death receptor-1-blocking antibody is approved as a single agent or in combination with chemotherapy
The supply of GLP-1 drugs for weight loss and diabetes treatment is expected to tighten this week with a federal deadline to halt the sale and production of off-brand products that many patients in the United States have come to rely on.
The Food and Drug Administration (FDA) announced Wednesday plans to help states and Indian tribes import cheaper prescription drugs from Canada. The initiative is in support of President Donald Trump’s executive order on May 12 which promised to deliver “most-favored nation prescription drug pricing” to America,
Johnson & Johnson has won the support of an FDA expert panel in its bid to make Darzalex the first treatment for an early form of multiple myeloma despite uncertainties raised by regulators.
Moderna filed for FDA approval of its mRNA-1083 combination shot last year. The submission put the biotech on track to win approval in adults aged 50 and older in November 2025. However, at the start of May, Moderna pushed back the expected approval date to 2026 after the FDA asked to see phase 3 efficacy before making a decision on authorization.